Table 7.
Messenger expression of genes involved in the pathogenic mechanisms of fatty liver showing 2-fold or greater regulation in liver between controls and MCDD rats treated with vehicle or CeO2NPs.
| Genes | MCDD rats | |
|---|---|---|
| Vehicle (n = 5) | CeO2NPs (n = 4) | |
| Insulin Signaling Pathway: | ||
| Igf1 | −2.14* | −4.27*,† |
| Igfbp1 | 43.05 | 16.71 |
| Pklr | −3.51** | −4.23** |
| Ppargc1a | 8.13 | 4.97** |
| Slc2a4 | −4.88 | −7.75* |
| Socs3 | 2.59 | 1.26 |
| Srebf1 | −1.75 | −3.27* |
| Adipokine Signaling Pathway: | ||
| Adipor1 | 2.09 | 1.05 |
| Cd36 | 7.25** | 3.23***,† |
| Lepr | 2.76 | −1.02† |
| Slc2a1 | 2.69 | 1.19 |
| Metabolic Pathways: | ||
| Acly | −2.18 | −2.82 |
| Abcg1 | 5.66* | 2.83* |
| Acaca | −2.17 | −4.17** |
| Acadl | 2.25 | 1.59 |
| Acsm3 | −1.61 | −2.76 |
| Apoa1 | 2.61* | 1.86* |
| Apoc3 | −1.92* | −2.83** |
| Atp5c1 | 2.14 | 1.21 |
| Cyp2e1 | 2.98 | 1.70 |
| Cyp7a1 | 2.50 | 2.18 |
| Cpt1a | 3.07* | 1.42† |
| Fabp3 | 3.35 | 2.05 |
| Fasn | −2.87 | −3.46 |
| G6pc | −1.24 | −2.02 |
| G6pd | 3.32 | 1.90** |
| Gck | 2.09 | 3.30 |
| Gk | 2.33* | 1.44 |
| Hmgcr | 3.07 | 1.98 |
| Lpl | 16.11* | 9.24** |
| Mlxipl | −1.64 | −2.34 |
| Nr1h4 | −2.18 | −2.46* |
| Pck2 | 6.25 | 4.35* |
| Pdk4 | 3.01 | 1.24 |
| Ppard | 2.96 | 1.69 |
| Scd1 | −45.15*** | −27.08** |
| Slc27a5 | −5.52** | −7.02* |
| Srebf2 | 2.42 | 1.23 |
| Inflammatory Response: | ||
| Il1B | 3.48* | 1.10† |
| Tnf | 6.33 | 2.65 |
| Apoptosis: | ||
| Casp3 | 2.34 | 1.14 |
| Fas | 4.41* | 2.29* |
| Serpine1 | 13.76* | 7.26* |
Abcg1, ATP-binding cassette, subfamily G (WHITE), member 1; Acaca, Acetyl-coenzyme A carboxylase alpha; Acadl, Acyl-CoA Dehydrogenase, Long Chain; Acly, ATP citrate lyase; Acsm3, Acyl-CoA synthetase medium-chain family member 3; Adipor1, Adiponectin receptor 1; ApoA1, apolipoprotein A-1; Apoc3, Apolipoprotein C-III; Atp5c1, ATP synthase subunit gamma, mitochondrial; Casp3, Caspase 3; Cd36, Cd36 molecule (thrombospondin receptor); Cpt1a, Carnitine palmitoyltransferase 1a, liver; Cyp2e1, Cytochrome P450, family 2, subfamily e, polypeptide 1; Cyp7a1, Cytochrome P450, family 7, subfamily a, polypeptide 1; Fabp3, Fatty acid binding protein 3, muscle and heart; Fas, Fas (TNF receptor superfamily, member 6); Fasn, Fatty acid synthase; G6pc, Glucose-6-phosphatase, catalytic subunit; G6pd, Glucose-6-phosphate dehydrogenase; Gck, Glucokinase; Gk, Glycerol kinase; Hmgcr, 3-hydroxy-3-methylglutaryl-Coenzyme A reductase; Igf1, Insulin-like growth factor 1; Igfbp1, Insulin-like growth factor binding protein 1; Il1B, Interleukin 1 beta; Lepr, leptin receptor; Lpl, Lipoprotein lipase; Mlxipl, MLX interacting protein-like; Nr1h4, Nuclear receptor subfamily 1, group H, member 4; Pck2, Phosphoenolpyruvate carboxykinase 2 (mitochondrial); Pdk4, Pyruvate dehydrogenase kinase, isozyme 4; Pklr, Pyruvate kinase, liver and RBC; Ppard, Peroxisome proliferator-activated receptor delta; Ppargc1a, Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; Scd1, Stearoyl-Coenzyme A desaturase 1; Serpine1, Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; Slc27a5, Solute carrier family 27 (fatty acid transporter), member 5; Slc2a1, Solute carrier family 2 (facilitated glucose transporter), member 1; Slc2a4, Solute carrier family 2 (facilitated glucose transporter), member 4; Socs3, Suppressor of cytokine signaling 3; Srebf1, Sterol regulatory element binding transcription factor 1; Srebf2, Sterol regulatory element binding transcription factor 2; Tnf, Tumor necrosis factor (TNF superfamily, member 2). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control rats. †p < 0.05 vs. MCDD rats receiving vehicle. Unpaired Student’s t-test.